Reprint

Advances in Cancer Therapy from Research to Clinical Practice—Surgical, Molecular or Systemic Management of Cancer

Edited by
September 2023
290 pages
  • ISBN978-3-0365-8782-0 (Hardback)
  • ISBN978-3-0365-8783-7 (PDF)

This book is a reprint of the Special Issue Advances in Cancer Therapy from Research to Clinical Practice—Surgical, Molecular or Systemic Management of Cancer that was published in

Biology & Life Sciences
Medicine & Pharmacology
Public Health & Healthcare
Summary

Cancer remains one of the most challenging diseases from an epidemiologic, clinical and therapeutic perspective. The rhythm of changes in various aspects of oncological diseases, the molecular characterization of new subtypes of classical primary-type tumors, new pathways in carcinogenesis and new classes of therapeutical agents make it very difficult to follow all relevant findings in this research field. Most significantly, what remains are each of our personal clinical observations and experiences. We all know the level of trust required in these matters, but we remain doctors who treat real-life patients, not those selected for clinical trials.

This Special Issue of Medicina was proposed in order to facilitate the presentation of the research or institutional experience of colleagues who are involved in treating cancer patients or are in the fundamental research field. Their clinical experience and research represent a very precious tool for each and every one of us.

Format
  • Hardback
License
© 2022 by the authors; CC BY-NC-ND license
Keywords
breast cancer (BC); invasive lobular carcinoma (ILC); insulin receptor substrate 4 (IRS-4); cyclooxygenase 2 (COX-2); cyclin D1; retinoblastoma protein 1 (Rb1); hepatocellular carcinoma; microwave thermotherapy; chemoembolization; recurrence; parathyroid carcinoma; well differentiated thyroid cancers; tumor association; preoperatory suspicion; en bloc resection; absolute iron deficiency; functional iron deficiency; colorectal cancer; acute hematologic malignancy; acute respiratory distress syndrome; pneumonia; leukostasis; diffuse alveolar hemorrhage; engraftment syndrome; radiation recall pneumonitis; transfusion-related acute lung injury; FKBPL; endometrioid endometrial carcinoma; angiogenesis; VEGF-A; estrogen receptor alpha; hepatic arterial infusion chemotherapy; hepatocellular carcinoma; transarterial chemoembolization; treatment failure; unsuitability; breast cancer; breast cancer prognosis; immune checkpoints; molecular tumor markers; PD-L1; polymorphisms; breast cancer; neoadjuvant therapy; pathological complete response; miR-375-3p; let-7e-5p; MiR-210-3p; drug delivery systems; polyurethane; cancer management; curcumin; release kinetics; pediatric oncology; lipomatosis; cisplatin; platinum-based chemotherapy; germ cell tumors; molecular subtypes; breast cancer; multiparametric MRI; ADC; luminal; 3dimensional reconstruction; von Hippel-Lindau disease; renal clear cells; kidney cancer; precursor structures; esophageal squamous cell carcinoma; neutrophil–mean-platelet-volume–platelet ratio; prognosis; biomarker; adrenal gland; 3D laparoscopic adrenalectomy; neuroblastoma; prostate cancer; obesity; overweight; body mass index; age; metastases; PSA; ovarian cancer; platinum resistance; platinum resistance mechanisms; overcoming platinum resistance; stage I testicular germ cell cancers; seminomatous—STC; non-seminomatous—NSTC; targeted therapy; BRAFi rechallenge; metastatic melanoma; BRAF V600 mutation; BRAF inhibitor; astrocytoma; IDH-mutation; multiple enchondroma; Maffucci syndrome; lung cancer; B-type Raf kinase (BRAF); immunohistochemistry; Ventana VE1 antibody; n/a